SOCM
ORKA

SR One Capital Management’s Oruka Therapeutics ORKA Stock Holding History

SR One Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1M Hold
430,330
– – 2.31% 10
2025
Q4 		$13M Hold
430,330
– – 1.85% 9
2025
Q3 		$8.28M Hold
430,330
– – 1.2% 8
2025
Q2 		$4.82M Hold
430,330
– – 1.05% 11
2025
Q1 		$4.42M Hold
430,330
– – 1.13% 10
2024
Q4 		$8.34M Buy
430,330
+55,000
+15% +$1.34M 2.03% 8
2024
Q3 		$9.2M Buy
+375,330
New +$13.1M 1.84% 9

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

SR One Capital Management's ORKA Position: Q1 2026 in Review

SR One Capital Management held its Oruka Therapeutics (ORKA) position steady in Q1 2026 at 430,330 shares worth $21.1M. The position accounts for 2.31% of the portfolio, ranked #10.

SR One Capital Management first reported a position in ORKA in Q3 2024 and has held it in 7 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • SR One Capital Management held 430,330 shares of Oruka Therapeutics worth $21.1M as of Q1 2026.
  • SR One Capital Management left its Oruka Therapeutics share count unchanged in Q1 2026.
  • Oruka Therapeutics made up 2.31% of SR One Capital Management's portfolio in Q1 2026, its #10 holding.
  • SR One Capital Management first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on SR One Capital Management's 13F filing for Q1 2026, filed 14 May 2026.